Smith & Nephew SNATS, Inc. $SNN Shares Purchased by Vanguard Personalized Indexing Management LLC

Vanguard Personalized Indexing Management LLC lifted its stake in Smith & Nephew SNATS, Inc. (NYSE:SNN) by 6.1% in the second quarter, HoldingsChannel reports. The fund owned 34,688 shares of the medical equipment provider’s stock after purchasing an additional 1,982 shares during the quarter. Vanguard Personalized Indexing Management LLC’s holdings in Smith & Nephew SNATS were worth $1,063,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. Armistice Capital LLC increased its stake in shares of Smith & Nephew SNATS by 258.1% during the first quarter. Armistice Capital LLC now owns 1,769,000 shares of the medical equipment provider’s stock valued at $50,187,000 after acquiring an additional 1,275,000 shares during the period. Goldman Sachs Group Inc. increased its position in shares of Smith & Nephew SNATS by 49.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,771,401 shares of the medical equipment provider’s stock valued at $50,255,000 after purchasing an additional 583,809 shares during the period. Oliver Luxxe Assets LLC acquired a new position in shares of Smith & Nephew SNATS during the 2nd quarter valued at $5,176,000. Northern Trust Corp raised its stake in shares of Smith & Nephew SNATS by 32.7% in the 1st quarter. Northern Trust Corp now owns 674,640 shares of the medical equipment provider’s stock worth $19,140,000 after buying an additional 166,248 shares in the last quarter. Finally, Causeway Capital Management LLC lifted its holdings in shares of Smith & Nephew SNATS by 26.3% in the first quarter. Causeway Capital Management LLC now owns 607,357 shares of the medical equipment provider’s stock valued at $17,231,000 after buying an additional 126,469 shares during the period. 25.64% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the company. Wall Street Zen lowered Smith & Nephew SNATS from a “strong-buy” rating to a “buy” rating in a report on Friday, October 3rd. Weiss Ratings restated a “hold (c+)” rating on shares of Smith & Nephew SNATS in a research report on Wednesday, October 8th. Sanford C. Bernstein set a $37.50 price objective on shares of Smith & Nephew SNATS and gave the stock a “market perform” rating in a research note on Tuesday. Finally, Canaccord Genuity Group increased their target price on shares of Smith & Nephew SNATS from $28.00 to $36.00 and gave the company a “hold” rating in a research note on Monday, August 18th. Eight research analysts have rated the stock with a Hold rating, According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $36.75.

Smith & Nephew SNATS Stock Performance

Shares of SNN opened at $36.35 on Friday. The company has a 50-day moving average of $36.71 and a two-hundred day moving average of $31.73. The stock has a market cap of $15.51 billion, a price-to-earnings ratio of 16.83, a PEG ratio of 0.99 and a beta of 0.69. The company has a debt-to-equity ratio of 0.60, a current ratio of 3.00 and a quick ratio of 1.40. Smith & Nephew SNATS, Inc. has a one year low of $23.69 and a one year high of $38.79.

Smith & Nephew SNATS Cuts Dividend

The company also recently disclosed a semi-annual dividend, which will be paid on Friday, November 7th. Shareholders of record on Friday, October 3rd will be given a dividend of $0.285 per share. This represents a yield of 165.0%. The ex-dividend date is Friday, October 3rd. Smith & Nephew SNATS’s payout ratio is presently 26.39%.

Smith & Nephew SNATS Profile

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT.